Company / Financials
Perspective Therapeutics, Inc. Financials
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.9M
FY2022 · +22.1% YoY
Net Income
-$7.3M
FY2022 · -41.4% YoY
Profit Margin
-249.9%
FY2022 · net income / revenue
ROE
-13.3%
FY2022 · return on equity
Total Assets
$58.1M
FY2022
Total Debt
-
FY2022
Equity
$54.6M
FY2022
ROA
-12.5%
FY2022 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.9M+22.1% YoYNet Income HistoryProfit after all expenses and taxes-$7.3M-41.4% YoYGross Profit HistoryRevenue minus cost of goods sold$0-100.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$6.2M+44.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$6.4M-22.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$5.6M+33.5% YoYR&D Expense HistoryResearch and development spending$850.0K-42.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$0Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.05